Compare · CWBR vs ORKA
CWBR vs ORKA
Side-by-side comparison of CohBar Inc. (CWBR) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CWBR and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $4.76B, about 172.8x CWBR ($27.6M).
- ORKA has hit the wire 3 times in the past 4 weeks while CWBR has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 1 for CWBR).
- Company
- CohBar Inc.
- Oruka Therapeutics Inc.
- Price
- $0.95+7.66%
- $74.43+3.39%
- Market cap
- $27.6M
- $4.76B
- 1M return
- -
- -21.61%
- 1Y return
- -
- +170.95%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 0
- 3
- Recent ratings
- 1
- 11
CohBar Inc.
CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, acute respiratory distress syndrome, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of nonalcoholic steatohepatitis (NASH) and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases, CB5064 analogs for COVID-19 associated ARDS, MBT5 analogs for CXCR4-related cancer and orphan diseases, and MBT3 analogs for cancer immunotherapy. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Latest CWBR
- SEC Form 25-NSE filed by CohBar Inc.
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
- CohBar Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CohBar Inc. filed SEC Form 8-K: Leadership Update, Other Events
- Why CohBar (CWBR) Stock Is Down Nearly 50% Today
- Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Latest ORKA
- SEC Form 4 filed by Oruka Therapeutics Inc.
- SEC Form 4 filed by Oruka Therapeutics Inc.
- Chief Executive Officer Klein Lawrence Otto exercised 25,000 shares at a strike of $7.80 and sold $2,090,593 worth of shares (25,000 units at $83.62) as part of a pre-agreed trading plan (SEC Form 4)
- Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing
- Senior Vice President, Finance Agarwal Arjun sold $51,035 worth of shares (533 units at $95.75) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 14,219 units (SEC Form 4)
- General Counsel Quinlan Paul T exercised 10,000 shares at a strike of $7.80 and sold $936,417 worth of shares (10,000 units at $93.64) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $734,145 worth of shares (7,947 units at $92.38) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 31,771 units (SEC Form 4) (for tax liability)
- Senior Vice President, Finance Agarwal Arjun sold $926,010 worth of shares (10,019 units at $92.43) as part of a pre-agreed trading plan and exercised 9,459 shares at a strike of $15.88, decreasing direct ownership by 4% to 14,752 units (SEC Form 4) (for tax liability)
- Chief Executive Officer Klein Lawrence Otto sold $234,681 worth of shares (2,452 units at $95.71), decreasing direct ownership by 0.26% to 923,128 units (SEC Form 4) to cover withholding tax
- General Counsel Quinlan Paul T sold $99,443 worth of shares (1,039 units at $95.71), decreasing direct ownership by 3% to 29,995 units (SEC Form 4) to cover withholding tax